XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

BACKGROUND: We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer. METHODS: NO16966 was a randomised, two-arm, non-inferiori...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cassidy, J, Clarke, S, Díaz-Rubio, E, Scheithauer, W, Figer, A, Wong, R, Koski, S, Rittweger, K, Gilberg, F, Saltz, L
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2011
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3137415/
https://ncbi.nlm.nih.gov/pubmed/21673685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.201
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars